Precision-components maker CDW Holding has, through its wholly-owned subsidiary Tomoike Bio Limited, entered into a master supplier agreement with Japanese cosmetics manufacturer Cosmo Beauty.
The agreement, which will see Tomoike Bio supplying a new skincare compound that combats anti-aging to Cosmo Beauty, will last till Dec 31.
The compound, which is named pterostilbene glycoside, is said to improve wrinkles by 20% on average after four weeks of daily use.
CDW patented a way to further enhance the potency of pterostilbene through a process known as glycosylation.
Glycosylation is commonly used to increase water solubility, absorbability, stability, and drug efficacy in pharmaceuticals, supplements and cosmetics.
The study conducted by CDW marks the first ever use of the compound in skincare and cosmetics.
The Japanese market for wrinkle-improving creams is highly lucrative. For instance, Japan’s fourth largest cosmetics company released its first facial wrinkle-fighting cream in 2017 and sales reached nearly 8.7 billion Japanese yen ($112 million) within the first six months.
“Demonstrating the superior efficacy of pterostilbene glycoside is an important development milestone, both for the company and the industry. We are the first company to harness the tremendous potential of pterostilbene glycoside in the skincare and cosmetic industry,” says Yoshikawa Makoto, CDW’s executive director and CEO.
The supplier agreement is not expected to have a significant material impact on the company’s performance for the financial year ending Dec 31.
Shares in CDW closed 0.5 cent lower or 1.8% down at 27 cents on Jan 28.
